Impact of Comorbidity on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results from the CARdiovascular in rheuMAtology (CARMA) study.
To evaluate the impact of comorbidities on the physical function in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Cross-sectional analysis of the baseline visit from the CARMA study. Multivariate models with physical function as the dependent variable (BASFI and HAQ for AS and PsA, respectively) were performed. A proxy for the Charlson Comorbidity Index (CCIp) (range: 0-27); sociodemographic data; disease activity (ESR and BASDAI in AS; DAS28-ESR in PsA); disease duration; radiographic damage and treatments. Results were reported as β-coefficients, 95% confidence intervals [95%CI] and p-values. We included 738 patients with AS and 721 with PsA; 21% of them had more than one comorbidity. Comorbidity burden (CCIp) was independently associated with worse adjusted physical function in patients with PsA (β: 0.11). Also, female sex (β: 0.14), disease duration (β: 0.01), disease activity (DAS28-ESR, β: 0.19), NSAIDs (β: 0.09), glucocorticoids (β: 0.11) and biologics (β: 0.15) were associated with worse function in patients with PsA. A higher educational level was associated with less disability (β: -0.14). In patients with AS, age (β: 0.03), disease activity (BASDAI; β: 0.81), radiographic damage (β: 0.61) and the use of biologics (β: 0.51) were independently associated with worse function on multivariate analyses, but CCIp was not. The presence of comorbidities in patients with PsA is independently associated with worse physical function. The detection and control of the comorbidities may yield an integral management of the disease. This article is protected by copyright. All rights reserved.